Literature DB >> 24963554

Our 2014 approach to breakthrough invasive fungal infections.

Georg Maschmeyer1, Thomas F Patterson.   

Abstract

Evidence-based clinical pathways to direct antifungal treatment options in patients with breakthrough fungal infections during current systemic antifungal therapy are not available. Nonetheless, for defined settings of such breakthrough infections approaches to management can be recommended based on clinical, epidemiological, pharmacological and in vitro susceptibility data.
© 2014 Blackwell Verlag GmbH.

Entities:  

Keywords:  Breakthrough fungal infection; echinocandins; fluconazole; liposomal AmB; posaconazole; voriconazole

Mesh：

Substances：

Year:  2014        PMID： 24963554     DOI： 10.1111/myc.12213

Source DB:  PubMed          Journal:  Mycoses        ISSN： 0933-7407            Impact factor:   4.377


  8 in total

1.  Prescribing Pattern of Antifungal Medications at a Tertiary Care Hospital in Oman.

Authors:  Khalid A Al Balushi; Mohammed A Alzaabi; Fatma Alghafri
Journal:  J Clin Diagn Res       Date:  2016-12-01

2.  A Single Center Experience for Antifungal Prophylaxis in Patients with Acute Myelogenous Leukemia.

Authors:  Gökhan Metan; Zeynep Türe; Çiğdem Pala; Leylagül Kaynar; Afra Yıldırım; Ferhan Elmalı; Nuri Tutar; Nuran Yozgat; Bülent Eser
Journal:  Indian J Hematol Blood Transfus       Date:  2014-11-02       Impact factor: 0.900

3.  Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.

Authors:  Eunmi Yang; Eun-Ji Choi; Han-Seung Park; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jung-Hee Lee; Je-Hwan Lee; Kyoo-Hyung Lee; Sung-Han Kim
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

Review 4.  Invasive mold infections in solid organ transplant recipients.

Authors:  Yoann Crabol; Olivier Lortholary
Journal:  Scientifica (Cairo)       Date:  2014-11-23

5.  Risk factors and clinical outcomes of breakthrough yeast bloodstream infections in patients with hematological malignancies in the era of newer antifungal agents.

Authors:  Si-Hyun Kim; Jae-Ki Choi; Sung-Yeon Cho; Hyo-Jin Lee; Sun Hee Park; Su-Mi Choi; Dong-Gun Lee; Jung-Hyun Choi; Jin-Hong Yoo; Jong-Wook Lee
Journal:  Med Mycol       Date:  2018-02-01       Impact factor: 4.076

Review 6.  Case reports of invasive mucormycosis associated neutropenic enterocolitis in leukemic children: diagnostic and treatment challenges and review of literature.

Authors:  Ali Amanati; Omid Reza Zekavat; Hamidreza Foroutan; Omidreza Azh; Ali Tadayon; Ahmad Monabati; Mohammad Hossein Anbardar; Haleh Bozorgi
Journal:  BMC Infect Dis       Date:  2021-12-20       Impact factor: 3.090

7.  Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study.

Authors:  Sun Bean Kim; Sung-Yeon Cho; Dong-Gun Lee; Jae-Ki Choi; Hyo-Jin Lee; Si-Hyun Kim; Sun Hee Park; Su-Mi Choi; Jung-Hyun Choi; Jin-Hong Yoo; Jong-Wook Lee
Journal:  Med Mycol       Date:  2017-04-01       Impact factor: 4.076

Review 8.  Lethal thrombosis of the iliac artery caused by Aspergillus fumigatus after liver transplantation: case report and review of the literature.

Authors:  Jan-Paul Gundlach; Rainer Günther; Helmut Fickenscher; Marcus Both; Christoph Röcken; Thomas Becker; Felix Braun
Journal:  BMC Surg       Date:  2019-12-27       Impact factor: 2.102
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.